No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AXSM240719C80000
- 4.90
- +2.40+96.00%
15min DelayClose Jul 19 15:59 ET
4.90High2.90Low
2.90Open2.50Pre Close23 Volume273 Open Interest80.00Strike Price8.81KTurnover715.00%IV0.06%PremiumJul 19, 2024Expiry Date4.85Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.8088Delta0.0457Gamma15.43Leverage Ratio-23.2272Theta0.0001Rho12.48Eff Leverage0.0023Vega
Intraday
- 5D
- Daily
News
Decoding 9 Analyst Evaluations For Axsome Therapeutics
Axsome Therapeutics (NASDAQ:AXSM) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below summarizes their recent
B of A Securities Maintains Neutral on Axsome Therapeutics, Lowers Price Target to $95
B of A Securities analyst Jason Gerberry maintains Axsome Therapeutics (NASDAQ:AXSM) with a Neutral and lowers the price target from $97 to $95.
Axsome Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/18/2024 15.29% B of A Securities $97 → $95 Maintains Neutral 06/12/2024 28.64% Mizuho $106 → $106
Express News | Axsome Therapeutics Inc : BofA Global Research Cuts Price Objective to $95 From $97
Citi Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Citi analyst David Hoang maintains $Axsome Therapeutics(AXSM.US)$ with a buy rating, and maintains the target price at $125.According to TipRanks data, the analyst has a success rate of 63.4% and a
Axsome Therapeutics: Stable Auvelity Growth and Coverage Amid New GPO Contract
Comments
$Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $Axsome Therapeutics(AXSM.US$ $Macrogenics(MGNX.US$
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
16
5
$Pfizer(PFE.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$ Phase 3
$Aquestive Therapeutics(AQST.US$ Phase 3
$Jaguar Health(JAGX.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$Johnson & Johnson(JNJ.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$ Phase 3
$Aquestive Therapeutics(AQST.US$ Phase 3
$Jaguar Health(JAGX.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$Johnson & Johnson(JNJ.US$ Phase 3
8
1
1. $Annovis Bio(ANVS.US$
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics(AXSM.US$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics(GTHX.US$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics(CRNX.US$
• Ph 3 data (PATHFND...
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics(AXSM.US$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics(GTHX.US$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics(CRNX.US$
• Ph 3 data (PATHFND...
7
🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
16
The strong revenue growth mirrors the robust share price gain. Top performers like Axsome Therapeutics can continue winning for decades. This seems like a good opportunity, despite the already positive sentiment.
Read more
Salmon Klein : are you in $Macrogenics (MGNX.US)$ ? tell me when good to jump in
MangoXXXX Salmon Klein: Now
Stoic Trader Salmon Klein: Do your own research , I think hovering in bottom and buy signal from pattern about to begin , do not follow me blindly my
Salmon Klein Stoic Trader: I am waiting to reach 14.8 or so, but I am busy working, if it reached the bottom and you are in...any good feedback is always very welcomed bro...just that so thanks
Stoic Trader Salmon Klein: Double higher bottom in intra-day might not hit below 14ish or if so still chance for 2 more trading sideways days, I am almost 25% down ( reason holding beyond top) anyway